Total | |
---|---|
(n = 149) | |
Age, yearsa | 49.3 ± 13.3 |
Gender, n (%) | |
Male | 67 (45.0) |
Female | 82 (55.0) |
Body mass index, kg/m2 a | 26.9 ± 4.3 |
Smoking status, n (%) | |
Current smoker | 0 |
Ex-smoker | 29 (19.5) |
Never smoked | 120 (80.5) |
Smoking history, pack-yearsa | 5.6 ± 2.5 |
Duration of asthma, yearsa | 23.8 ± 13.4 |
FEV1a | |
% of predicted value pre-bronchodilation at screeningb | 71.3 ± 7.1 |
% of predicted value post-bronchodilation at screeningb | 87.4 ± 10.2 |
Reversibility, Lb | 0.500 ± 0.239 |
% reversibilityb | 22.8 ± 10.2 |
Pre-dose at study baseline, Lc | 2.306 ± 0.689 |
FVC, pre-dose at baselinec, La | 3.639 ± 0.978 |
FEV1/FVC ratio at baselinec, %a | 63.7 ± 10.1 |
ICS dose of stable maintenance treatment, μga,d | 659.2 ± 249.4 |